Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris.

Bernard C, Sougakoff W, Fournier A, Larnaudie S, Antoun F, Robert J, Brossier F, Truffot-Pernot C, Jarlier V, Veziris N.

Int J Tuberc Lung Dis. 2012 May;16(5):649-55. doi: 10.5588/ijtld.11.0241. Epub 2012 Mar 8.

PMID:
22410620
2.

[Bacteriological tests for tuberculosis].

Truffot-Pernot C, Veziris N.

Rev Mal Respir. 2011 Oct;28(8):1034-47. doi: 10.1016/j.rmr.2011.07.002. Epub 2011 Oct 10. Review. French.

PMID:
22099409
3.

Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W.

Antimicrob Agents Chemother. 2011 Jan;55(1):355-60. doi: 10.1128/AAC.01030-10. Epub 2010 Oct 25.

4.

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N.

Am J Respir Crit Care Med. 2009 Sep 15;180(6):553-7. doi: 10.1164/rccm.200807-1152OC. Epub 2009 Jul 9.

PMID:
19590024
5.

A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.

Veziris N, Ibrahim M, Lounis N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V.

Am J Respir Crit Care Med. 2009 Jan 1;179(1):75-9. doi: 10.1164/rccm.200711-1736OC. Epub 2008 Oct 23.

PMID:
18948422
6.

A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995-2004.

Khuê PM, Truffot-Pernot C, Texier-Maugein J, Jarlier V, Robert J.

Eur Respir J. 2007 Nov;30(5):937-44. Epub 2007 Jun 13.

7.

Mycobacterium szulgai infection in a captive population of African clawed frogs (Xenopus tropicalis).

Chai N, Deforges L, Sougakoff W, Truffot-Pernot C, De Luze A, Demeneix B, Clément M, Bomsel MC.

J Zoo Wildl Med. 2006 Mar;37(1):55-8.

PMID:
17312814
8.

An intervention programme for the management of multidrug-resistant tuberculosis in France.

Uffredi ML, Truffot-Pernot C, Dautzenberg B, Renard M, Jarlier V, Robert J.

Int J Antimicrob Agents. 2007 Apr;29(4):434-9. Epub 2007 Feb 14.

PMID:
17300920
9.

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.

Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N.

Antimicrob Agents Chemother. 2007 Mar;51(3):1011-5. Epub 2006 Dec 18.

10.

[Trends in tuberculosis treatment duration].

Veziris N, Aubry A, Truffot-Pernot C.

Presse Med. 2006 Nov;35(11 Pt 2):1758-1764. doi: 10.1016/S0755-4982(06)74895-3. Review. French.

PMID:
17086138
11.

[Modern diagnosis of tuberculosis].

Truffot-Pernot C, Véziris N, Sougakoff W.

Presse Med. 2006 Nov;35(11 Pt 2):1739-1746. doi: 10.1016/S0755-4982(06)74892-8. Review. French.

PMID:
17086135
12.
13.

Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.

Matrat S, Veziris N, Mayer C, Jarlier V, Truffot-Pernot C, Camuset J, Bouvet E, Cambau E, Aubry A.

Antimicrob Agents Chemother. 2006 Dec;50(12):4170-3. Epub 2006 Oct 2.

14.

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V.

Antimicrob Agents Chemother. 2006 Nov;50(11):3543-7. Epub 2006 Sep 5.

15.

Hip prosthesis infection due to Mycobacterium wolinskyi.

Pulcini C, Vandenbussche E, Podglajen I, Sougakoff W, Truffot-Pernot C, Buu-Hoï A, Varon E, Mainardi JL.

J Clin Microbiol. 2006 Sep;44(9):3463-4.

16.

Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.

Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM.

Antimicrob Agents Chemother. 2006 Jan;50(1):104-12.

17.

Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

Veziris N, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V.

Antimicrob Agents Chemother. 2005 Oct;49(10):4015-9.

18.

Outbreak of tuberculosis in a migrants' shelter, Paris, France, 2002.

Valin N, Antoun F, Chouaïd C, Renard M, Dautzenberg B, Lalande V, Ayache B, Morin P, Sougakoff W, Thiolet JM, Truffot-Pernot C, Jarlier V, Decludt B.

Int J Tuberc Lung Dis. 2005 May;9(5):528-33.

PMID:
15875924
19.

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V.

Science. 2005 Jan 14;307(5707):223-7. Epub 2004 Dec 9.

20.

First isolation of Mycobacterium microti (Llama-type) from a dog.

Deforges L, Boulouis HJ, Thibaud JL, Boulouha L, Sougakoff W, Blot S, Hewinson G, Truffot-Pernot C, Haddad N.

Vet Microbiol. 2004 Nov 15;103(3-4):249-53.

PMID:
15504596
21.

[Utility of molecular tools in diagnosis, treatment, and epidemiology of mycobacterial infections].

Veziris N, Aubry A, Sougakoff W, Truffot-Pernot C, Jarlier V.

Med Trop (Mars). 2004;64(3):243-9. Review. French. No abstract available.

PMID:
15497323
22.

Use of a high-density DNA probe array for detecting mutations involved in rifampicin resistance in Mycobacterium tuberculosis.

Sougakoff W, Rodrigue M, Truffot-Pernot C, Renard M, Durin N, Szpytma M, Vachon R, Troesch A, Jarlier V.

Clin Microbiol Infect. 2004 Apr;10(4):289-94.

23.

[Mycobacterium fortuitum skin infection occurring after a facelift].

Angeli K, Lacour JP, Mantoux F, Roujeau JC, André P, Truffot-Pernot C, Ortonne JP.

Ann Dermatol Venereol. 2004 Feb;131(2):198-200. French.

PMID:
15026750
24.

Multiple cerebral abscesses as a complication of Mycobacterium fortuitum infection.

Marie I, Héron F, Lecomte F, Jarlier V, Truffot-Pernot C, Laquerriere A, Huerre M, Levesque H, Courtois H.

Eur J Intern Med. 2003 Oct;14(6):386-389.

PMID:
14769500
25.

Multidrug-resistant tuberculosis: eight years of surveillance in France.

Robert J, Trystram D, Truffot-Pernot C, Jarlier V.

Eur Respir J. 2003 Nov;22(5):833-7.

26.

Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.

Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N.

Antimicrob Agents Chemother. 2003 Oct;47(10):3117-22.

27.

Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.

Lounis N, Maslo C, Truffot-Pernot C, Grosset J, Boelaert RJ.

Int J Tuberc Lung Dis. 2003 Jun;7(6):575-9.

PMID:
12797701
28.

Disseminated infection with a mycobacterium related to Mycobacterium triplex with central nervous system involvement associated with AIDS.

Zeller V, Nardi AL, Truffot-Pernot C, Sougakoff W, Stankoff B, Katlama C, Bricaire F.

J Clin Microbiol. 2003 Jun;41(6):2785-7. Review.

29.

Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes.

Dauendorffer JN, Guillemin I, Aubry A, Truffot-Pernot C, Sougakoff W, Jarlier V, Cambau E.

J Clin Microbiol. 2003 Mar;41(3):1311-5.

30.

Impacts of interleukin-12 on multiplication of Mycobacterium tuberculosis and Mycobacterium avium complex in mice.

Lounis N, Ji B, Truffot-Pernot C, Ridley RG, Alber G, Grosset JH.

Clin Microbiol Infect. 1999 Jun;5(6):331-338.

31.

[Mycobacterium xenopi, a newcomer?].

Grosset J, Truffot-Pernot C.

Rev Prat. 1998 Apr 1;48(7):701-3. French. No abstract available.

PMID:
11767362
32.

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.

Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, Roscigno G, Grosset J.

Antimicrob Agents Chemother. 2001 Dec;45(12):3482-6.

33.

Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.

Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J.

Antimicrob Agents Chemother. 2001 Nov;45(11):3229-30.

34.

Rapid, simple, and culture-independent detection of rpsL codon 43 mutations that are highly predictive of streptomycin resistance in Mycobacterium tuberculosis.

Mieskes KT, Rüsch-Gerdes S, Truffot-Pernot C, Feldmann K, Tortoli E, Casal M, Löscher T, Rinder H.

Am J Trop Med Hyg. 2000 Jul-Aug;63(1-2):56-60.

PMID:
11357996
35.

Mycobacterial growth indicator tube versus the proportion method on Löwenstein-Jensen medium for antibiotic susceptibility testing of Mycobacterium tuberculosis.

Cambau E, Truffot-Pernot C, Boulahbal F, Wichlacz C, Grosset J, Jarlier V.

Eur J Clin Microbiol Infect Dis. 2000 Dec;19(12):938-42.

PMID:
11205631
36.

Iron and Mycobacterium tuberculosis infection.

Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR.

J Clin Virol. 2001 Feb;20(3):123-6. Review.

PMID:
11166659
37.

Antibiotic susceptibility pattern of Mycobacterium marinum.

Aubry A, Jarlier V, Escolano S, Truffot-Pernot C, Cambau E.

Antimicrob Agents Chemother. 2000 Nov;44(11):3133-6.

38.

Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group.

Robert J, Trystram D, Truffot-Pernot C, Carbonnelle B, Grosset J.

Int J Tuberc Lung Dis. 2000 Jul;4(7):665-72.

PMID:
10907770
39.

Twenty-five years of tuberculosis in a French university hospital: a laboratory perspective.

Robert J, Trystram D, Truffot-Pernot C, Cambau E, Jarlier V, Grosset J.

Int J Tuberc Lung Dis. 2000 Jun;4(6):504-12.

PMID:
10864180
40.

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.

Daniel N, Lounis N, Ji B, O'Brien RJ, Vernon A, Geiter LJ, Szpytma M, Truffot-Pernot C, Hejblum G, Grosset J.

Am J Respir Crit Care Med. 2000 May;161(5):1572-7.

PMID:
10806157
41.

A national survey of human Mycobacterium bovis infection in France. Network of Microbiology Laboratories in France.

Robert J, Boulahbal F, Trystram D, Truffot-Pernot C, de Benoist AC, Vincent V, Jarlier V, Grosset J.

Int J Tuberc Lung Dis. 1999 Aug;3(8):711-4.

PMID:
10460104
43.

Evaluation of the new MB redox system for detection of growth of mycobacteria.

Cambau E, Wichlacz C, Truffot-Pernot C, Jarlier V.

J Clin Microbiol. 1999 Jun;37(6):2013-5.

44.

Mycobacterium avium complex common-source or cross-infection in AIDS patients attending the same day-care facility.

Carbonne A, Lemaitre N, Bochet M, Truffot-Pernot C, Katlama C, Grosset J, Bricaire F, Jarlier V.

Infect Control Hosp Epidemiol. 1998 Oct;19(10):784-6.

PMID:
9801289
45.

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J.

Antimicrob Agents Chemother. 1998 Aug;42(8):2066-9.

46.

Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers.

Lemaître N, Sougakoff W, Truffot-Pernot C, Cambau E, Derenne JP, Bricaire F, Grosset J, Jarlier V.

Int J Tuberc Lung Dis. 1998 May;2(5):390-6.

PMID:
9613635
47.

Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.

Grosset J, Lounis N, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Ji B.

Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1436-40.

PMID:
9603120
48.

[The bacteriology of tuberculosis and non-tuberculosis mycobacterial infections].

Wyplosz B, Truffot-Pernot C, Robert J, Jarlier V, Grosset J.

Rev Mal Respir. 1997 Dec;14 Suppl 5:S33-48. Review. French.

PMID:
9496590
49.

Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice.

Lounis N, Ji B, Truffot-Pernot C, Grosset J.

Antimicrob Agents Chemother. 1997 May;41(5):1168-9.

50.

Mycobacterial lung disease in cystic fibrosis: a prospective study.

Fauroux B, Delaisi B, Clément A, Saizou C, Moissenet D, Truffot-Pernot C, Tournier G, Vu Thien H.

Pediatr Infect Dis J. 1997 Apr;16(4):354-8.

PMID:
9109135

Supplemental Content

Loading ...
Support Center